VTE did not affect survival in lenalidomide/dexamethasone-treated multiple myeloma

December 2009
Hem/Onc Today;12/10/2009, Vol. 10 Issue 23, p64
The article discusses research which compared the effects of lenalidomide plus high-dose dexamethasone against dexamethasone plus placebo in multiple myeloma patients who developed venous thromboembolism, conducted by M. Zangari, published in a 2009 issue of the "Journal of Clinical Oncology."


Related Articles

  • Lenalidomide.  // Reactions Weekly;12/1/2007, Issue 1180, p23 

    The article describes the case of a 7-year-old man who developed severe hepatotoxicity, characterised by hyperbilirubinaemia, after receiving lenalidomide for stage IIIB multiple myeloma. The patient had initially received thalidomide and dexamethasone for multiple myeloma. He developed fatigue...

  • Lenalidomide.  // Reactions Weekly;2/20/2016, Vol. 1589 Issue 1, p138 

    An abstract of the article "Clinical analysis of thromboembolism associated with lenalidomide based regimens for multiple myeloma patients" by X. Qu and others is presented.

  • Aspirin, warfarin may reduce thromboembolic events in multiple myeloma.  // Hem/Onc Today;3/25/2011, Vol. 12 Issue 6, p14 

    The article reports that fixed-dose warfarin or aspirin showed comparable efficiency as low-molecular-weight heparin in cutting the risk for thromboembolic events in myeloma patients who received regimens with thalidomide, which is based on a study involving 659 patients.

  • Aspirin for VTE prophylaxis in multiple myeloma questioned.  // Reactions Weekly;8/24/2013, Issue 1466, p4 

    An abstract of the article "MELISSE, a large multicentric observational study to determine risk factors of venous thromboembolism in patients with multiple myeloma treated with immunomodulatory drugs," by X. Leleu is presented.

  • Consensus guidelines for the optimal management of adverse events in newly diagnosed, transplant-ineligible patients receiving melphalan and prednisone in combination with thalidomide (MPT) for the treatment of multiple myeloma. Palumbo, A.; Davies, F.; Kropff, M.; Bladé, J.; Delforge, M.; Costa, F. Leal Da; Garcia Sanz, R.; Schey, S.; Facon, T.; Morgan, G.; Moreau, P. // Annals of Hematology;Aug2010, Vol. 89 Issue 8, p803 

    Thalidomide has received approval from the European Agency for the Evaluation of Medicinal Products for the treatment of newly diagnosed multiple myeloma (MM) patients older than 65 years or ineligible for transplant. The results of five phase III trials assessing thalidomide in combination with...

  • Thromboprophylaxis with LMWH, warfarin, low-dose aspirin, safe in newly diagnosed multiple myeloma.  // Hem/Onc Today;1/10/2010, Vol. 11 Issue 1, p18 

    This article focuses on a study which investigated the efficacy and safety of thromboprophylaxis with low-molecular weight heparin, warfarin or low-dose aspirin in preventing venous thromboembolism in patients with multiple myeloma.

  • Thromboembolic Complications in Malignant Haematological Disorders. Castelli, Roberto; Ferrari, Barbara; Cortelezzi, Agostino; Guariglia, Achille // Current Vascular Pharmacology;Jul2010, Vol. 8 Issue 4, p482 

    It is well known that solid cancers are associated with thromboembolic complications, but recent studies have shown that the incidence of thrombosis may be as high (or even higher) in patients with malignant haematological disorders. However, this may be obscured by the significant morbidity and...

  • MGUS and Myeloma May Predispose to Venous Thromboembolism. Artz, Andrew S. // Clinical Oncology Alert;Dec2008, Vol. 24 Issue 12, p92 

    Recent studies have suggested that multiple myeloma and monoclonal gammopathy of unknown significance (MGUS) may predispose to venous thromboembolism, even in untreated patients. The authors retrospectively reviewed Veteran Affairs hospital discharge records from 1980 to 1996 for the diagnosis...

  • The International Pharmacopoeia.  // WHO Drug Information;2010, Vol. 24 Issue 2, p115 

    The article provides drug information on the antiretroviral drugs emtricitabine and tenofovir including information on the manufacture and storage of the drugs and tests that can be used to identify the drugs.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics